News & Updates

Initial findings from the ongoing VIVID-2 open-label extension (OLE) study comprising week 52 endoscopic responders from the phase III VIVID-1 trial demonstrate the long-term clinical and endoscopic efficacy of the selective anti-interleukin-23p19 monoclonal antibody mirikizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).

Escalating the dose of subcutaneous (SC) CT-P13, a biosimilar of infliximab, from 120 to 240 mg every 2 weeks appears to bring back the efficacy of the drug in patients with inflammatory bowel disease (IBD) who no longer respond to treatment, suggests a study presented at 2025 Crohn's & Colitis Congress.

For survivors of intracerebral haemorrhage (ICH) with atrial fibrillation (AF), the use of direct oral anticoagulants (DOACs) works to prevent ischaemic stroke events, but this benefit appears to be offset by major bleeding side effects, as shown in the open-label, phase III PRESTIGE-AF trial.

Data presented at SMFM 2025 favour nifedipine over labetalol for the management of hypertension in the postpartum period.

Treatment with peginterferon (PegIFN) α-2b appears to inhibit the growth of and thyroid function in children with chronic hepatitis B (CHB), suggests a study.